145 related articles for article (PubMed ID: 11571736)
41. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
42. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
[TBL] [Abstract][Full Text] [Related]
43. The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma.
Pinato DJ; Mauri FA; Lloyd T; Vaira V; Casadio C; Boldorini RL; Sharma R
Br J Cancer; 2013 Feb; 108(3):621-8. PubMed ID: 23361052
[TBL] [Abstract][Full Text] [Related]
44. [Pleural mesothelioma: morphology, histochemistry, difficulties in diagnosis and nosologic problems (author's transl)].
Abelanet R; Jagueux M; Fondimare A; Roujeau J
Rev Fr Mal Respir; 1979; 7(3):243-64. PubMed ID: 91185
[TBL] [Abstract][Full Text] [Related]
45. Assessment of the value of fibronectin as a tumour marker in malignant pleural mesothelioma.
Emri S; Ustündağ Y; Budak T; Karakoca Y; Ozdemir O
Monaldi Arch Chest Dis; 1997 Aug; 52(4):335-8. PubMed ID: 9401361
[TBL] [Abstract][Full Text] [Related]
46. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
Neragi-Miandoab S; Richards WG; Sugarbaker DJ
Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
[TBL] [Abstract][Full Text] [Related]
47. Glycosaminoglycans of pleural mesothelioma: a possible biochemical variant containing chondroitin sulfate.
Iozzo RV; Goldes JA; Chen WJ; Wight TN
Cancer; 1981 Jul; 48(1):89-97. PubMed ID: 6786728
[TBL] [Abstract][Full Text] [Related]
48. Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma.
Jennings CJ; O'Grady A; Cummins R; Murer B; Al-Alawi M; Madden SF; Mutti L; Harvey BJ; Thomas W; Kay EW
J Thorac Oncol; 2012 Jan; 7(1):243-8. PubMed ID: 22011668
[TBL] [Abstract][Full Text] [Related]
49. Unusual features of malignant pleural mesothelioma metastatic to the mediastinal lymph nodes.
Wagner D; Bourne PA; Yang Q; Goldman BI; Lewis JS; Xu H
Appl Immunohistochem Mol Morphol; 2008 May; 16(3):301-7. PubMed ID: 18301236
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
Schramm A; Opitz I; Thies S; Seifert B; Moch H; Weder W; Soltermann A
Eur J Cardiothorac Surg; 2010 Mar; 37(3):566-72. PubMed ID: 19781955
[TBL] [Abstract][Full Text] [Related]
51. Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor.
Alì G; Boldrini L; Lucchi M; Mussi A; Corsi V; Fontanini G
J Thorac Oncol; 2009 Mar; 4(3):348-54. PubMed ID: 19155997
[TBL] [Abstract][Full Text] [Related]
52. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
Kirschner MB; Pulford E; Hoda MA; Rozsas A; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; László V; Klikovits T; Vallely MP; Grusch M; Hegedus B; Dome B; Klepetko W; van Zandwijk N; Klebe S; Reid G
Br J Cancer; 2015 Sep; 113(6):963-9. PubMed ID: 26263483
[TBL] [Abstract][Full Text] [Related]
53. Glycosaminoglycans in malignant diffuse mesothelioma.
Kawai T; Suzuki M; Shinmei M; Maenaka Y; Kageyama K
Cancer; 1985 Aug; 56(3):567-74. PubMed ID: 4005813
[TBL] [Abstract][Full Text] [Related]
54. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
Rusch VW; Niedzwiecki D; Tao Y; Menendez-Botet C; Dnistrian A; Kelsen D; Saltz L; Markman M
J Clin Oncol; 1992 Jun; 10(6):1001-6. PubMed ID: 1588364
[TBL] [Abstract][Full Text] [Related]
55. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.
Strizzi L; Catalano A; Vianale G; Orecchia S; Casalini A; Tassi G; Puntoni R; Mutti L; Procopio A
J Pathol; 2001 Apr; 193(4):468-75. PubMed ID: 11276005
[TBL] [Abstract][Full Text] [Related]
56. G-CSF-producing malignant pleural mesothelioma: an autopsy case report with literature review.
Oka K; Sarashina G; Yonekawa N; Watanabe O; Miyao Y; Hashimoto T; Yatabe Y
Int J Surg Pathol; 2012 Jun; 20(3):272-5. PubMed ID: 21911431
[TBL] [Abstract][Full Text] [Related]
57. Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype.
Beer TW; Buchanan R; Matthews AW; Stradling R; Pullinger N; Pethybridge RJ
Hum Pathol; 1998 Mar; 29(3):246-51. PubMed ID: 9496827
[TBL] [Abstract][Full Text] [Related]
58. Is survivin expression prognostic or predictive in malignant pleural mesothelioma?
Hmeljak J; Erčulj N; Dolžan V; Pižem J; Kern I; Kovač V; Cemažar M; Cör A
Virchows Arch; 2013 Mar; 462(3):315-21. PubMed ID: 23358691
[TBL] [Abstract][Full Text] [Related]
59. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
Sherman ME; Mark EJ
Arch Pathol Lab Med; 1990 Aug; 114(8):845-51. PubMed ID: 2375659
[TBL] [Abstract][Full Text] [Related]
60. Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.
Welker L; Müller M; Holz O; Vollmer E; Magnussen H; Jörres RA
Virchows Arch; 2007 Apr; 450(4):455-61. PubMed ID: 17377812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
